| scholarly article | Q13442814 |
| P2093 | author name string | A X Zhu | |
| C S Fuchs | |||
| C C Earle | |||
| D P Ryan | |||
| R J Mayer | |||
| A Muzikansky | |||
| J A Meyerhardt | |||
| M H Kulke | |||
| J W Clark | |||
| L S Blaszkowsky | |||
| M M Vincitore | |||
| P C Enzinger | |||
| P Fidias | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma | Q36611088 | ||
| Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma | Q36614148 | ||
| Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial | Q36616002 | ||
| Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer | Q36648325 | ||
| Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer | Q39436075 | ||
| Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer | Q40800385 | ||
| CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study | Q45714364 | ||
| Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. | Q46467199 | ||
| Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group | Q46960507 | ||
| One-sample multiple testing procedure for phase II clinical trials | Q70365924 | ||
| Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design | Q72732581 | ||
| The treatment of advanced gastric cancer: in search of the right combination | Q74000573 | ||
| P433 | issue | 3 | |
| P921 | main subject | docetaxel | Q420436 |
| multicenter clinical trial | Q6934595 | ||
| irinotecan | Q412197 | ||
| cisplatin | Q412415 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 475-480 | |
| P577 | publication date | 2009-01-12 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer | |
| P478 | volume | 20 |
| Q35222202 | Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress |
| Q37627676 | Docetaxel: its role in current and future treatments for advanced gastric cancer |
| Q89391950 | Gastric cancer |
| Q27011232 | Novel immunotherapeutic strategies of gastric cancer treatment |
| Q33434339 | Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer |
| Q84178293 | Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus |
| Q34205672 | Targeted therapies for gastric cancer: current status |
| Q34661367 | Treatment options in patients with metastatic gastric cancer: current status and future perspectives |
| Q38565576 | Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer |
Search more.